Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

Fig. 1

Frequently used frontline treatment regimens for patients with NDMM (a) who did not receive stem cell transplant (non-transplant) and (b) who received stem cell transplant (transplant). NDMM Newly diagnosed multiple myeloma, Vd Bortezomib/dexamethasone, Rd Lenalidomide/dexamethasone, VRd Bortezomib/lenalidomide/dexamethasone, V/alkylator Bortezomib/alkylating agent, V Bortezomib, R Lenalidomide, T Thalidomide. aOther regimens include other combinations of novel agents, such as Td and VR, as well as treatment with cyclophosphamide-containing regimens

Back to article page
\